D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 19

PMID 38891871

Authors

Agota Barabassy

Zsofia Borbala Dombi

Gyorgy Nemeth

Affiliations

Soon will be listed here.

Abstract

Until the late 1800s, drug development was a chance finding based on observations and repeated trials and errors. Today, drug development must go through many iterations and tests to ensure it is safe, potent, and effective. This process is a long and costly endeavor, with many pitfalls and hurdles. The aim of the present review article is to explore what is needed for a molecule to move from the researcher bench to the patients' bedside, presented from an industry perspective through the development program of cariprazine. Cariprazine is a relatively novel antipsychotic medication, approved for the treatment of schizophrenia, bipolar mania, bipolar depression, and major depression as an add-on. It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients' bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.

References

Carpenter D . Gatekeeping and the FDA's Role in Human Subjects Protection. Virtual Mentor. 2012; 6(11). DOI: 10.1001/virtualmentor.2004.6.11.msoc1-0411. View

Mohr P, Masopust J, Kopecek M . Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?. Front Psychiatry. 2022; 12:781946. PMC: 8821167. DOI: 10.3389/fpsyt.2021.781946. View

Graff-Guerrero A, Mamo D, Shammi C, Mizrahi R, Marcon H, Barsoum P . The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry. 2009; 66(6):606-15. DOI: 10.1001/archgenpsychiatry.2009.43. View

Mueller-Langer F . Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?. Health Econ Policy Law. 2013; 8(2):185-208. PMC: 3592259. DOI: 10.1017/S1744133112000321. View

Torrisi S, Geraci F, Contarini G, Salomone S, Drago F, Leggio G . Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside. Curr Top Behav Neurosci. 2022; 60:133-156. DOI: 10.1007/7854_2022_326. View

Morup M, Kymes S, Astrom D . A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States. PLoS One. 2020; 15(6):e0234121. PMC: 7272089. DOI: 10.1371/journal.pone.0234121. View

Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G . The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2014; 17(1):63-75. DOI: 10.1111/bdi.12238. View

Sacks L, Shamsuddin H, Yasinskaya Y, Bouri K, Lanthier M, Sherman R . Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA. 2014; 311(4):378-84. DOI: 10.1001/jama.2013.282542. View

Heffernan M, Herman L, Brown S, Jones P, Shao L, Hewitt M . Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. ACS Med Chem Lett. 2022; 13(1):92-98. PMC: 8762745. DOI: 10.1021/acsmedchemlett.1c00527. View

10.

Potkin S, Kane J, Correll C, Lindenmayer J, Agid O, Marder S . The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020; 6(1):1. PMC: 6946650. DOI: 10.1038/s41537-019-0090-z. View

11.

Sykes D, Dowling M, Charlton S . Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds. Curr Protoc Pharmacol. 2012; Chapter 9:Unit 9.14. DOI: 10.1002/0471141755.ph0914s50. View

12.

Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y . Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 2018; 204:282-288. DOI: 10.1016/j.schres.2018.08.020. View

13.

Schlander M, Hernandez-Villafuerte K, Cheng C, Mestre-Ferrandiz J, Baumann M . How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics. 2021; 39(11):1243-1269. PMC: 8516790. DOI: 10.1007/s40273-021-01065-y. View

14.

Leucht S, Davis J . Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017; 389(10074):1077-1078. DOI: 10.1016/S0140-6736(17)30181-2. View

15.

Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S . Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res. 2011; 131(1-3):63-8. DOI: 10.1016/j.schres.2011.05.005. View

16.

Kiss B, Kramos B, Laszlovszky I . Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D Receptors in the Brain . Front Psychiatry. 2022; 13:785592. PMC: 8987915. DOI: 10.3389/fpsyt.2022.785592. View

17.

Grinchii D, Dremencov E . Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. Int J Mol Sci. 2020; 21(24). PMC: 7765178. DOI: 10.3390/ijms21249532. View

18.

Booze R, Wallace D . Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse. 1995; 19(1):1-13. DOI: 10.1002/syn.890190102. View

19.

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

20.

Ramachandraih C, Subramanyam N, Bar K, Baker G, Yeragani V . Antidepressants: From MAOIs to SSRIs and more. Indian J Psychiatry. 2011; 53(2):180-2. PMC: 3136031. DOI: 10.4103/0019-5545.82567. View